TGF-β and tumors - an ill-fated alliance

Current Opinion in Immunology

Volumn 20, Issue 2, 2008, Pages 234-240

  Moutsopoulos, Niki M ^a   Wen, Jie ^a   Wahl, Sharon M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; PROTEINASE; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL SURVIVAL; CYTOKINE RELEASE; HEAD AND NECK CARCINOMA; HELPER CELL; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 44749094914     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.04.003     Document Type: Review

References (50)

1. Smyth M.J., Dunn G.P., and Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90 (2006) 1-50
2. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315 (1986) 1650-1659
3. Egeblad M., Littlepage L.E., and Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 70 (2005) 383-388
4. Denardo D.G., Johansson M., and Coussens L.M. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27 (2008) 11-18
5. Basak S., Kim H., Kearns J.D., Tergaonkar V., O'Dea E., Werner S.L., Benedict C.A., Ware C.F., Ghosh G., Verma I.M., et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128 (2007) 369-381. Identification of the inflammatory molecule NFκB2/p100 as a link to carcinogenesis based on its ability to overactivate the developmental pathway.
6. Wahl S.M. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 19 (2007) 55-62. Describes potential underlying mechanisms that regulate the apparent opposing proinflammatory and immunosuppressive effects of TGF-β.
7. Levy L., and Hill C.S. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17 (2006) 41-58
8. Roberts A.B., and Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100 (2003) 8621-8623
9. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., Gomis R.R., Manova-Todorova K., and Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446 (2007) 765-770. Study identifies four genes that synergistically promote tumor progression and demonstrate that inactivation of these genes abrogates primary tumor growth and metastasis in a mouse breast cancer model.
10. Wahl S.M., Wen J., and Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 213 (2006) 213-227
11. Jewett A., Head C., and Cacalano N.A. Emerging mechanisms of immunosuppression in oral cancers. J Dent Res 85 (2006) 1061-1073
12. Lu S.L., Reh D., Li A.G., Woods J., Corless C.L., Kulesz-Martin M., and Wang X.J. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 64 (2004) 4405-4410
13. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., and Weaver C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006) 231-234. First evidence that TGF-β is a lineage commitment factor for murine Th17 lymphocytes.
14. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., Oukka M., and Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 (2007) 484-487
15. + T helper cells. Cell 126 (2006) 1121-1133. Identifies RORγt as the relevant transcription factor in Th17 lineage commitment.
16. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., Hishinuma T., Goto J., Lotze M.T., Kolls J.K., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175 (2005) 6177-6189
17. + cells. Evidence of a dichotomous effect of IL-2 on Treg and Th17.
18. Stockinger B., Veldhoen M., and Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol 19 6 (2007) 353-361
19. Brandt K., Singh P.B., Bulfone-Paus S., and Ruckert R. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev 18 (2007) 223-232
20. Skak K., Kragh M., Hausman D., Smyth M.J., and Sivakumar P.V. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 7 3 (2008) 231-240
21. Nakano H., Kishida T., Asada H., Shin-Ya M., Shinomiya T., Imanishi J., Shimada T., Nakai S., Takeuchi M., Hisa Y., et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med 8 (2006) 90-99
22. Chen Z., and O'Shea J.J. Th17 cells: a new fate for differentiating helper T cells. Immunol Res (2008) Jan 3; [Epub ahead of print]
23. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R.A., and Oft M. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
24. Kaiga T., Sato M., Kaneda H., Iwakura Y., Takayama T., and Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 178 (2007) 7571-7580
25. Overwijk W.W., de Visser K.E., Tirion F.H., de Jong L.A., Pols T.W., van der Velden Y.U., van den Boorn J.G., Keller A.M., Buurman W.A., Theoret M.R., et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 176 (2006) 5213-5222
26. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 (2007) 419-426
27. Ito M., Minamiya Y., Kawai H., Saito S., Saito H., Nakagawa T., Imai K., Hirokawa M., and Ogawa J. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 176 (2006) 5637-5643
28. + T cell cytotoxicity and cancer. Semin Cancer Biol 16 (2006) 124-136
29. Warburton G., Nikitakis N.G., Roberson P., Marinos N.J., Wu T., Sauk Jr. J.J., Ord R.A., and Wahl S.M. Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. J Oral Maxillofac Surg 65 (2007) 475-484
30. Strauss L., Volland D., Kunkel M., and Reichert T.E. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med Sci Monit 11 (2005) BR280-BR292
31. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7 (2001) 1118-1122
32. Ahmadzadeh M., and Rosenberg S.A. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174 (2005) 5215-5223
33. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198 (2003) 1741-1752
34. Bergmann C., Strauss L., Zeidler R., Lang S., and Whiteside T.L. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67 (2007) 8865-8873
35. + regulatory T cells. Immunol Rev 212 (2006) 60-73
36. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 (2003) 1875-1886
37. + regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 14 (2003) 85-89
38. + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13 (2007) 4345-4354
39. Wahl S.M., Wen J., and Moutsopoulos N.M. The kiss of death: interrupted by NK-cell close encounters of another kind. Trends Immunol 27 4 (2006) 161-164
40. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 (2007) 1167-1174
41. Ghiringhelli F., Menard C., Martin F., and Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 214 (2006) 229-238
42. Zwirner N.W., Fuertes M.B., Girart M.V., Domaica C.I., and Rossi L.E. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 18 (2007) 159-170
43. + regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 30 (2007) 203-214
44. + T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 178 (2007) 6840-6848. Depletion of Treg is more effective in early compared to late stages of cancer.
45. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102 (2005) 18538-18543
46. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 12 (2006) 465-472
47. Turner M.S., Cohen P.A., and Finn O.J. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol 178 (2007) 2787-2793
48. Kaminska B., Wesolowska A., and Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 52 (2005) 329-337
49. Truty M.J., and Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology 7 (2007) 423-435
50. Nair S., Boczkowski D., Fassnacht M., Pisetsky D., and Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67 (2007) 371-380. Targeting Treg through vaccination against Foxp3 enhances tumor immunity.